DK2504012T3 - Anvendelse af en triterpenholdig oleogel til sårheling - Google Patents
Anvendelse af en triterpenholdig oleogel til sårheling Download PDFInfo
- Publication number
- DK2504012T3 DK2504012T3 DK10784299.9T DK10784299T DK2504012T3 DK 2504012 T3 DK2504012 T3 DK 2504012T3 DK 10784299 T DK10784299 T DK 10784299T DK 2504012 T3 DK2504012 T3 DK 2504012T3
- Authority
- DK
- Denmark
- Prior art keywords
- oleogel
- triterpene
- use according
- weight
- containing powder
- Prior art date
Links
- 230000029663 wound healing Effects 0.000 title claims description 24
- 150000003648 triterpenes Chemical class 0.000 claims description 59
- 206010052428 Wound Diseases 0.000 claims description 57
- 208000027418 Wounds and injury Diseases 0.000 claims description 57
- 239000000843 powder Substances 0.000 claims description 33
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 claims description 16
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 claims description 16
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 claims description 11
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 claims description 11
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims description 8
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims description 8
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 8
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims description 8
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 8
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 8
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 8
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 claims description 8
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims description 8
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims description 8
- 229940100243 oleanolic acid Drugs 0.000 claims description 8
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 6
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 claims description 5
- PSZDOEIIIJFCFE-UHFFFAOYSA-N Oleanolic alcohol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C)(C)CC5C4=CCC3C21C PSZDOEIIIJFCFE-UHFFFAOYSA-N 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- PSZDOEIIIJFCFE-OSQDELBUSA-N erythrodiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PSZDOEIIIJFCFE-OSQDELBUSA-N 0.000 claims description 4
- HTZRWCSRPTWJCT-UHFFFAOYSA-N erythrodiol Natural products CC1(C)CCC2(CO)CCC3C(CCC4C3(C)CCC5C(C)(C)C(O)CCC45C)C2C1 HTZRWCSRPTWJCT-UHFFFAOYSA-N 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- 238000013532 laser treatment Methods 0.000 claims description 3
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 235000021302 avocado oil Nutrition 0.000 claims description 2
- 239000008163 avocado oil Substances 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000010773 plant oil Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 27
- 230000035876 healing Effects 0.000 description 21
- 239000000203 mixture Substances 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 239000000499 gel Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 238000009826 distribution Methods 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000018185 Betula X alpestris Nutrition 0.000 description 4
- 235000018212 Betula X uliginosa Nutrition 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229960003949 dexpanthenol Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000037309 reepithelialization Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003357 wound healing promoting agent Substances 0.000 description 3
- 235000004866 D-panthenol Nutrition 0.000 description 2
- 239000011703 D-panthenol Substances 0.000 description 2
- 235000014066 European mistletoe Nutrition 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 244000152640 Rhipsalis cassutha Species 0.000 description 2
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011437 continuous method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- -1 for example Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- BZNIIOGSANMIET-JEKRXEKZSA-N Allobetulin Natural products O[C@@H]1C(C)(C)[C@H]2[C@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H]6C(C)(C)CC[C@]5(CO6)CC4)CC3)CC2)CC1 BZNIIOGSANMIET-JEKRXEKZSA-N 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001083912 Cotyledon orbiculata Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 description 1
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BZNIIOGSANMIET-UHFFFAOYSA-N allobetuline Natural products CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3)(C)C2CCC1C1C2OCC13CCC2(C)C BZNIIOGSANMIET-UHFFFAOYSA-N 0.000 description 1
- BZNIIOGSANMIET-HWNNWUPFSA-N allobetulinol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]([C@]1(C)CC3)(C)[C@@H]2CC[C@@H]1[C@H]1[C@H]2OC[C@]13CCC2(C)C BZNIIOGSANMIET-HWNNWUPFSA-N 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 description 1
- 208000007150 epidermolysis bullosa simplex Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940048400 fucidin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- NKMDIWKRKQFYPH-VIUFNMEASA-N lupane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C NKMDIWKRKQFYPH-VIUFNMEASA-N 0.000 description 1
- 125000003179 lupane group Chemical group 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- LOBOFOUJCFGHAP-UHFFFAOYSA-N n-octyl-1-[10-(4-octyliminopyridin-1-yl)decyl]pyridin-4-imine;2-phenoxyethanol;dihydrochloride Chemical compound Cl.Cl.OCCOC1=CC=CC=C1.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 LOBOFOUJCFGHAP-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000000744 recessive dystrophic epidermolysis bullosa Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 238000011120 smear test Methods 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Colloid Chemistry (AREA)
- Fats And Perfumes (AREA)
Claims (17)
1. Oleogel til anvendelse ved sårheling, som indeholder en upolær væske og et triterpenholdigt pulver som oleogeldanner, idet det triterpenholdige pulver har betulin og lupeol, og en fælles andel af betulin og lupeol i det triterpenholdige pulver er større end 80 vægt-%.
2. Oleogel til anvendelse ifølge krav 1 til anvendelse ved sårheling i re-epithelialiseringsfasen.
3. Oleogel til anvendelse ifølge krav 1 eller 2, som har: en upolær væske med en andel mellem 80 vægt-% og 99 vægt-% baseret på den samlede vægt af gelen, et triterpenholdigt pulver som oleogeldanner med en andel mellem 1 vægt-% og 2 0 vægt-% baseret på den samlede vægt af gelen.
4. Oleogel til anvendelse ifølge krav 3 hvor andelen af den upolære væske er mellem 88 vægt-% og 94 vægt-%, og andelen af oleogeldanneren er mellem 6 vægt-% og 12 vægt-%.
5. Oleogel til anvendelse ifølge et af de foregående krav hvor den upolære væske er en vegetabilsk, animalsk, mineralsk eller syntetisk olie.
6. Oleogel til anvendelse ifølge krav 5 hvor olien er en planteolie, som er udvalgt af følgende: solsikkeolie, olivenolie, avocadoolie, mandelolie.
7. Oleogel til anvendelse ifølge et af de foregående krav hvor det triterpenholdige pulver har en triterpenandel på mere end 80 vægt-%.
8. Oleogel til anvendelse ifølge et af de foregående krav hvor det triterpenholdige pulver har en triterpenandel på mere end 90 vægt-%.
9. Oleogel til anvendelse ifølge krav 8 hvor en andel af betulin i triterpenandelen udgør mere end 50 vægt-% eller mere end 60 vægt-%.
10. Oleogel til anvendelse ifølge et af de foregående krav hvor en gennemsnitlig partikelstørrelse i det triterpenholdige pulver er mellem 20nm og 50μ.
11. Oleogel til anvendelse ifølge krav 10 hvor en gennemsnitlig partikelstørrelse i det triterpenholdige pulver er mindre end 10μ.
12. Oleogel til anvendelse ifølge et af de foregående krav til anvendelse ved sårheling af sår ved Epidermolysis bullosa.
13. Oleogel til anvendelse ifølge et af kravene 1 til 11 til anvendelse ved sårheling af sår, som er opstået ved udtagelse af hud til transplantation.
14. Oleogel til anvendelse ifølge et af kravene 1 til 11 til anvendelse ved sårheling af sår, som er opstået ved en laserbehandling af huden.
15. Oleogel til anvendelse ifølge et af de foregående krav som endvidere omfatter en sårhelende substans.
16. Oleogel til anvendelse ifølge et af de foregående krav hvor den fælles andel af betulin og lupeol i det triterpenholdige pulver er større end 85 vægt-%.
17. Oleogel til anvendelse ifølge et af de foregående krav hvor det triterpenholdige pulver endvidere har: betulinsyre, oleanolsyre, erythrodiol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009047092A DE102009047092A1 (de) | 2009-11-24 | 2009-11-24 | Verwendung eines triterpenhaltigen Oleogels zur Wundheilung |
| PCT/EP2010/068157 WO2011064271A2 (de) | 2009-11-24 | 2010-11-24 | Verwendung eines triterpenhaltigen oleogels zur wundheilung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2504012T3 true DK2504012T3 (da) | 2016-07-18 |
Family
ID=43627016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10784299.9T DK2504012T3 (da) | 2009-11-24 | 2010-11-24 | Anvendelse af en triterpenholdig oleogel til sårheling |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9352041B2 (da) |
| EP (1) | EP2504012B1 (da) |
| JP (3) | JP6017959B2 (da) |
| KR (2) | KR101822589B1 (da) |
| CN (1) | CN102665723B (da) |
| AU (1) | AU2010323158B2 (da) |
| BR (1) | BR112012012499B8 (da) |
| CA (1) | CA2781229C (da) |
| CO (1) | CO6541607A2 (da) |
| CY (1) | CY1117865T1 (da) |
| DE (1) | DE102009047092A1 (da) |
| DK (1) | DK2504012T3 (da) |
| EA (1) | EA023983B1 (da) |
| ES (1) | ES2576832T3 (da) |
| HR (1) | HRP20160727T1 (da) |
| HU (1) | HUE028566T2 (da) |
| IL (1) | IL220008A (da) |
| LT (1) | LT2504012T (da) |
| MX (1) | MX339924B (da) |
| NZ (1) | NZ600759A (da) |
| PL (1) | PL2504012T3 (da) |
| PT (1) | PT2504012E (da) |
| RS (1) | RS55089B1 (da) |
| SI (1) | SI2504012T1 (da) |
| WO (1) | WO2011064271A2 (da) |
| ZA (1) | ZA201203784B (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009047092A1 (de) * | 2009-11-24 | 2011-05-26 | Birken Gmbh | Verwendung eines triterpenhaltigen Oleogels zur Wundheilung |
| CZ20996U1 (cs) * | 2010-05-06 | 2010-06-14 | RNDr. Jan Šarek, Ph.D. - Betulinines | Topický prípravek |
| DE102011106393A1 (de) | 2011-07-02 | 2013-01-03 | Steffen Herr | Doppellagiges textiles Flächengebilde mit einstellbaren, festem Lagenabstand in der Verwendung als Wundauflage |
| DE102012007919A1 (de) | 2012-04-20 | 2013-10-24 | Steffen Herr | Doppellagiges textiles Flächengebilde mit einstellbaren, festem Lagenabstand in der Verwendung als Wundauflage |
| WO2018017576A1 (en) * | 2016-07-18 | 2018-01-25 | Rolf Daniels | Betulin-containing water-in-oil foams and compositions thereof |
| CN106178068B (zh) * | 2016-08-18 | 2017-09-19 | 广州华弘生物科技有限公司 | 一种促进伤口愈合的贴膜及缝合器 |
| CN107049865B (zh) * | 2017-04-27 | 2018-03-27 | 养生堂（上海）化妆品研发有限公司 | 护肤化妆品组合物 |
| CN107019660B (zh) | 2017-04-27 | 2018-05-11 | 养生堂（上海）化妆品研发有限公司 | 保湿化妆品组合物 |
| CN109418683A (zh) * | 2017-09-01 | 2019-03-05 | 莲创药业股份有限公司 | 冬瓜蜡在作为防腐剂和抗微生物剂中的用途 |
| WO2019083771A1 (en) * | 2017-10-23 | 2019-05-02 | Microcures, Inc. | METHOD FOR IMPROVING THE RECOVERY OF A SKIN TREATED WITH A COSMETIC LASER |
| CN111356479A (zh) | 2018-01-04 | 2020-06-30 | 安瑞特研究有限公司 | 含有白桦脂醇的桦树皮提取物及其制剂 |
| CN108478847B (zh) * | 2018-03-08 | 2021-02-09 | 上海君联医疗设备有限公司 | 用于治疗创伤的油沙布及其制备方法 |
| EP3583954A1 (en) | 2018-06-19 | 2019-12-25 | neubourg skin care GmbH | Nanodispersions of birch bark extract, electrospun fibers containing such nanodispersions and their use for the treatment of wounds |
| CN109512780A (zh) * | 2019-01-09 | 2019-03-26 | 河南省医药科学研究院 | 一种凝胶药膏及其制备方法和应用 |
| US12544386B2 (en) | 2019-05-15 | 2026-02-10 | Ichilov Tech Ltd | Method and composition for treatment of skin diseases associated with accelerated corneodesmosomes degradation or weaker cell-cell adhesion |
| RU2724342C1 (ru) * | 2019-06-25 | 2020-06-23 | федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО "ПИМУ" Минздрава России) | Композиция для лечения заболеваний кожи и косметического использования |
| CN115998671B (zh) * | 2021-10-23 | 2024-12-20 | 北京嘉桦生物技术有限公司 | 一种桦树汁温敏型原位凝胶在烧烫伤皮肤修复中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4142224A (en) | 1977-09-09 | 1979-02-27 | Westinghouse Electric Corp. | Control center bus bars |
| JPS61205204A (ja) * | 1985-03-08 | 1986-09-11 | Shiseido Co Ltd | 皮膚外用剤 |
| JPH09235293A (ja) * | 1996-02-29 | 1997-09-09 | Kanebo Ltd | 新規トリテルペン |
| CA2280093A1 (en) * | 1997-02-04 | 1998-08-06 | John V. Kosbab | Compositions and methods for prevention and treatment of vascular degenerative diseases |
| US5750578A (en) | 1997-02-11 | 1998-05-12 | Regents Of The University Of Minnesota | Use of betulin and analogs thereof to treat herpesvirus infection |
| US6022890A (en) | 1997-11-14 | 2000-02-08 | Merck & Co., Inc. | Immunosuppressant tetracyclic triterpenes |
| WO2001019365A1 (en) * | 1999-09-15 | 2001-03-22 | Roche Consumer Health Ag | Pharmaceutical and/or cosmetical compositions |
| EA013736B1 (ru) | 2000-03-28 | 2010-06-30 | Биркен Гмбх | Эмульсия, содержащая растительный экстракт, в частности экстракт берёзовой коры, и ее применение |
| CN1427707A (zh) * | 2000-03-31 | 2003-07-02 | 日清制油株式会社 | 皮肤外用剂和增白剂 |
| DE10237281A1 (de) | 2002-08-14 | 2004-03-04 | Birken Gmbh | Vorrichtung zur kontinuierlichen Extraktion von Extraktstoffen aus Pflanzen |
| DE10317400B4 (de) | 2003-04-15 | 2006-04-13 | Universitätsklinikum Hamburg-Eppendorf | EX-VIVO-Hautorganmodell aus Schweinehaut |
| DE10329955A1 (de) | 2003-07-03 | 2005-02-03 | Merck Patent Gmbh | Verwendung eines hydroalkoholischen Extrakts aus Bauhinia zur Herstellung einer Zubereitung |
| DE102004030044A1 (de) | 2004-06-22 | 2006-01-12 | Birken Gmbh | Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels |
| US8293710B2 (en) | 2005-01-03 | 2012-10-23 | Blue Blood Biotech Corp. | Method for treating wounds using an EGF-like domain of thrombomodulin |
| US20090041859A1 (en) * | 2005-04-08 | 2009-02-12 | Mie University | Wound Treatment Drugs for External Use |
| BRPI0613227A2 (pt) | 2005-06-09 | 2011-01-04 | Chiang Chuan Chi | uma composição para cicatrização de ferida e uso desta |
| JP2007277135A (ja) * | 2006-04-05 | 2007-10-25 | Mie Univ | 創傷治療用外用剤 |
| DE102006049929B4 (de) * | 2006-10-19 | 2012-03-08 | Beiersdorf Ag | Filmbildende Gelkomposition zur Wund- bzw. Hautpflege |
| GB2455585B (en) | 2008-01-16 | 2010-07-28 | Ali Reza Rezai-Fard | Capsicum seeds for the treatment of eczema and dermatitis |
| DE102009047092A1 (de) * | 2009-11-24 | 2011-05-26 | Birken Gmbh | Verwendung eines triterpenhaltigen Oleogels zur Wundheilung |
-
2009
- 2009-11-24 DE DE102009047092A patent/DE102009047092A1/de not_active Ceased
-
2010
- 2010-11-24 CN CN201080053092.XA patent/CN102665723B/zh active Active
- 2010-11-24 EA EA201290381A patent/EA023983B1/ru not_active IP Right Cessation
- 2010-11-24 SI SI201031202A patent/SI2504012T1/sl unknown
- 2010-11-24 US US13/509,416 patent/US9352041B2/en active Active
- 2010-11-24 KR KR1020157004184A patent/KR101822589B1/ko active Active
- 2010-11-24 NZ NZ600759A patent/NZ600759A/en unknown
- 2010-11-24 HU HUE10784299A patent/HUE028566T2/en unknown
- 2010-11-24 CA CA2781229A patent/CA2781229C/en active Active
- 2010-11-24 PT PT107842999T patent/PT2504012E/pt unknown
- 2010-11-24 DK DK10784299.9T patent/DK2504012T3/da active
- 2010-11-24 LT LTEP10784299.9T patent/LT2504012T/lt unknown
- 2010-11-24 KR KR1020127016341A patent/KR20120105014A/ko not_active Ceased
- 2010-11-24 MX MX2012005769A patent/MX339924B/es active IP Right Grant
- 2010-11-24 HR HRP20160727TT patent/HRP20160727T1/hr unknown
- 2010-11-24 PL PL10784299.9T patent/PL2504012T3/pl unknown
- 2010-11-24 BR BR112012012499A patent/BR112012012499B8/pt active IP Right Grant
- 2010-11-24 WO PCT/EP2010/068157 patent/WO2011064271A2/de not_active Ceased
- 2010-11-24 EP EP10784299.9A patent/EP2504012B1/de active Active
- 2010-11-24 RS RS20160444A patent/RS55089B1/sr unknown
- 2010-11-24 ES ES10784299.9T patent/ES2576832T3/es active Active
- 2010-11-24 JP JP2012540422A patent/JP6017959B2/ja active Active
- 2010-11-24 AU AU2010323158A patent/AU2010323158B2/en active Active
-
2012
- 2012-05-23 ZA ZA2012/03784A patent/ZA201203784B/en unknown
- 2012-05-24 IL IL220008A patent/IL220008A/en active IP Right Grant
- 2012-05-24 CO CO12086128A patent/CO6541607A2/es not_active Application Discontinuation
-
2014
- 2014-10-03 JP JP2014204951A patent/JP2014240444A/ja active Pending
-
2016
- 2016-04-29 US US15/142,679 patent/US9827214B2/en active Active
- 2016-06-22 CY CY20161100560T patent/CY1117865T1/el unknown
- 2016-08-04 JP JP2016153396A patent/JP6263239B2/ja active Active
-
2017
- 2017-10-24 US US15/792,277 patent/US20180263937A1/en not_active Abandoned
-
2018
- 2018-06-18 US US16/010,995 patent/US20180296508A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2504012T3 (da) | Anvendelse af en triterpenholdig oleogel til sårheling | |
| US5179086A (en) | Topical ointment | |
| AU2005261569A1 (en) | Pharmaceutical composition comprising an ointment and two solubilized active principles | |
| AU710479B2 (en) | Antiglucocorticoid medicament | |
| RU2361594C2 (ru) | Фармацевтические композиции, включающие комбинацию кальцитриола и клобетазола пропионат | |
| CN103877117A (zh) | 一种丁酸氢化可的松氧化锌药物组合物 | |
| EP4371551A1 (en) | Molecular assembly of bile acid or bile salt and pharmaceutical composition comprising same for removing local fat | |
| RU2859799C1 (ru) | Средство для лечения воспалительных дерматозов, в том числе осложненных бактериальной и/или грибковой инфекцией | |
| CN120899879A (zh) | 一种抗敏止痒及治疗皮肤炎性相关疾病的多肽组合制剂 | |
| CN101947200B (zh) | 一种乳化型软膏 | |
| JP2024525831A (ja) | 胆汁酸または胆汁酸塩の分子会合体及びこれを含む局所脂肪除去用の医薬組成物 | |
| UA128615C2 (uk) | Мазь емульсійна на остові фітокомплексу для терапії хейлітів різної етіології | |
| RU2553600C2 (ru) | Фармацевтическая композиция для лечения заболеваний кожи | |
| CN114796113A (zh) | 一种艾纳香油纳米乳剂在制备抗肿瘤药物及创伤修复药物中的应用 | |
| WO2017188843A1 (ru) | Лечебно-косметическое средство для профилактики и комплексного лечения дерматозов | |
| BR112018010727B1 (pt) | Composição farmacêutica tópica | |
| CN107530362A (zh) | 皮肤用的药物组合物 | |
| RS20140193A1 (sr) | Preparat i postupak za dobijanje preparata za lečenje dermatitisa i ekcema |